Vitamin Shoppe (NYSE:VSI) issued its earnings results on Tuesday. The specialty retailer reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.03, Bloomberg Earnings reports. Vitamin Shoppe had a positive return on equity of 6.17% and a negative net margin of 20.27%. The business had revenue of $268.77 million during the quarter, compared to the consensus estimate of $269.24 million. During the same quarter last year, the company earned $0.36 EPS. The firm’s revenue was down 11.8% compared to the same quarter last year.
Shares of Vitamin Shoppe (NYSE VSI) opened at $3.90 on Wednesday. The stock has a market capitalization of $103.10, a PE ratio of -0.37 and a beta of 0.59. The company has a current ratio of 2.07, a quick ratio of 0.32 and a debt-to-equity ratio of 0.59. Vitamin Shoppe has a 12-month low of $2.95 and a 12-month high of $23.25.
In related news, major shareholder Vintage Capital Management Llc purchased 133,804 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The shares were acquired at an average cost of $4.28 per share, with a total value of $572,681.12. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Shah Capital Management purchased 300,000 shares of the firm’s stock in a transaction on Monday, February 5th. The stock was bought at an average cost of $3.83 per share, for a total transaction of $1,149,000.00. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 1,000,639 shares of company stock valued at $4,387,647. Corporate insiders own 1.07% of the company’s stock.
Several brokerages have commented on VSI. Zacks Investment Research upgraded Vitamin Shoppe from a “strong sell” rating to a “hold” rating in a research note on Sunday, January 21st. ValuEngine downgraded Vitamin Shoppe from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. Barclays cut their target price on Vitamin Shoppe from $6.00 to $3.00 and set an “equal weight” rating for the company in a research note on Thursday, November 9th. Finally, Morgan Stanley cut their target price on Vitamin Shoppe from $7.50 to $4.00 and set an “equal weight” rating for the company in a research note on Thursday, November 9th. Three research analysts have rated the stock with a sell rating and six have given a hold rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $5.00.
Vitamin Shoppe Company Profile
Vitamin Shoppe, Inc (VSI) is a multi-channel specialty retailer and contract manufacturer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. The Company operates through three segments: retail, direct and manufacturing. The retail segment includes Vitamin Shoppe, Super Supplements and Vitapath retail store formats.
Receive News & Ratings for Vitamin Shoppe Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe and related companies with MarketBeat.com's FREE daily email newsletter.